by HTLV | Sep 26, 2026 | Publications
Biomolecules. 2026 Sep 9;16(9):1310. doi: 10.3390/biom16091310. ABSTRACT Replication stress (RS) represents a major vulnerability of cancer cells treated with nucleoside analogs and related antimetabolites; however, tumors frequently acquire tolerance mechanisms that...
by HTLV | Sep 26, 2026 | Publications
J Clin Med. 2026 Sep 11;15(18):7058. doi: 10.3390/jcm15187058. ABSTRACT Background: Transfusion-transmitted infections (TTIs) continue to threaten the safety of blood supply systems worldwide. This study aimed to estimate the prevalence of malaria, HTLV I/II, and...
by HTLV | Sep 23, 2026 | Publications
Front Immunol. 2026 Sep 8;17:1919613. doi: 10.3389/fimmu.2026.1919613. eCollection 2026. ABSTRACT Adult T-cell leukemia/lymphoma (ATLL) is an aggressive HTLV-1-associated T-cell neoplasm, and durable control of relapsed/refractory disease remains difficult without...
by HTLV | Sep 23, 2026 | Publications
Mol Biol Rep. 2026 Sep 22;53(1):1603. doi: 10.1007/s11033-026-12778-8. ABSTRACT Human retroviruses, including Human Immunodeficiency Virus Type 1 (HIV-1) and Human T-cell Leukemia Virus Type 1 (HTLV-1), remain major global health challenges because of their ability to...
by HTLV | Sep 20, 2026 | Publications
Cancer Treat Res Commun. 2026 Sep 19;49:101448. doi: 10.1016/j.ctarc.2026.101448. Online ahead of print. ABSTRACT The transcriptional coactivators p300 and CREB-binding protein (CBP) integrate chromatin remodeling, enhancer activity, lysine acetylation, immune...
by HTLV | Sep 11, 2026 | Publications
JCO Glob Oncol. 2026 Sep;12(9):e2600265. doi: 10.1200/GO-26-00265. Epub 2026 Sep 11. ABSTRACT PURPOSE: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is an aggressive, heterogeneous subtype of non-Hodgkin lymphoma with poor prognosis and limited...
